首页 | 本学科首页   官方微博 | 高级检索  
     


Synthesis,Molecular Docking,In Vitro and In Vivo Studies of Novel Dimorpholinoquinazoline-Based Potential Inhibitors of PI3K/Akt/mTOR Pathway
Authors:Maria V. Zapevalova  Ekaterina S. Shchegravina  Irina P. Fonareva  Diana I. Salnikova  Danila V. Sorokin  Alexander M. Scherbakov  Alexander A. Maleev  Stanislav K. Ignatov  Ivan D. Grishin  Alexander N. Kuimov  Maryia V. Konovalova  Elena V. Svirshchevskaya  Alexey Yu. Fedorov
Abstract:A (series) range of potential dimorpholinoquinazoline-based inhibitors of the PI3K/Akt/mTOR cascade was synthesized. Several compounds exhibited cytotoxicity towards a panel of cancer cell lines in the low and sub-micromolar range. Compound 7c with the highest activity and moderate selectivity towards MCF7 cells which express the mutant type of PI3K was also tested for the ability to inhibit PI3K-(signaling pathway) downstream effectors and associated proteins. Compound 7c inhibited the phosphorylation of Akt, mTOR, and S6K at 125–250 nM. It also triggered PARP1 cleavage, ROS production, and cell death via several mechanisms. Inhibition of PI3Kα was observed at a concentration of 7b 50 µM and of 7c 500 µM and higher, that can indicate minority PI3Kα as a target among other kinases in the titled cascade for 7c. In vivo studies demonstrated an inhibition of tumor growth in the colorectal tumor model. According to the docking studies, the replacement of the triazine core in gedatolisib (8) by a quinazoline fragment, and incorporation of a (hetero)aromatic unit connected with the carbamide group via a flexible spacer, can result in more selective inhibition of the PI3Kα isoform.
Keywords:dimorpholinoquinazoline   cancer   PI3K/Akt/mTOR inhibitor   S6K   kinase inhibition activity
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号